Want to submit or suggest content for the MiMedia Clinical Library?
Contact us here
EPG Online is not responsible for external content
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
| Drug class description : | Antivirals. |
| Generic Name : | Ribavirin [tribavirin] |
| Drug description : | Capsules. |
| Presentation : | Capsules, ribavirin 200mg . |
| Indications : | In combination with interferon alfa-2b for the treatment of chronic hepatitis C in interferon alfa naive patients and those who have relapsed following previous interferon alfa therapy. |
| Adult Dosage : | Under 75kg, two in the morning and three in the evening; over 75kg, three in the morning and three in the evening. Administer interferon alfa-2b 3 mega units by subcutaneous injection three times per week. Continue treatment for six months in relapse patients and for minimum 24 weeks in naive patients. |
| Child Dosage : | Under 18 years, not recommended. |
| Contra Indications : | Severe cardiac disease, haemoglobinopathies (thalassemia, sickle-cell anaemia), chronic renal failure, history of severe renal failure, history of severe psychiatric conditions, severe hepatic impairment, liver cirrhosis, autoimmune disease, uncontrolled thyroid disorders. Pregnancy: must have a negative pregnancy test just before initiating therapy, and effective contraception must be used during and for 4 months after treatment. Teratogenic risk also extends to female partners of male patients, effective contraception must be used during and for 7 months after treatment. Counsel patients about teratogenic effects and need for contraception, continue pregnancy testing during therapy. Lactation. |
| Special Precautions : | Closely monitor renal and cardiac function, haematological values and blood chemistry before and at 2 - 4 week intervals during therapy; discontinue if any deterioration. Congestive heart failure, myocardial infarction, arrhythmia; perform ECG before and during therapy. Withdraw if acute hypersensitivity, liver function abnormalities, psychiatric or thyroid disorders develop. Gout. |
| Interactions : | Nucleoside reverse transcriptase inhibitors (NRTIs). |
| Adverse Reactions : | Haemolysis, anaemia, psychiatric disorders, suicidal ideation, thyroid disorders, hyperuricaemia. |
| Manufacturer : | Schering-Plough |
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org